Serum IL-6 is a prognostic biomarker for advanced hepatocellular carcinoma treated with atezolizumab and bevacizumab Lorenz Kocheise; Jan Kempski; Yunhe Tang; Lorenz Balcar; Victoria Berger; Miriam Tomczak; Joao Gorgulho; Ramsha Masood; Franziska Giehren; Constantin Schmidt; Jan P. Sutter; Thorben W. Fruendt; Francesca Pagani; Sophie Wulf; Julian Kött; Saskia Domanig; Anastasios Giannou; Tanja Bedke; Jöran Lücke; Tao Zhang; Siwen Zhang; Andres Machicote; Ansgar W. Lohse; Marianna Alunni-Fabbroni; Jens Ricke; Najib Ben Khaled; Matthias Pinter; Bernhard Scheiner; Samuel Huber; Johann von Felden; Ignazio Piseddu; Kornelius Schulze;

Liver decompensation is a frequent cause of treatment discontinuation and prognostic factor in intermediate-advanced HCC Federico Piñero; Margarita Anders; Carla Bermudez; Ezequiel Demirdjian; Adriana Varón; Ana Palazzo; Jorge Rodriguez; Oscar Beltrán; Leonardo Gomes da Fonseca; Ezequiel Ridruejo; Pablo Caballini; Norberto Tamagnone; Virginia Reggiardo; Hugo Cheinquer; Alexandre Araujo; Diego Arufe; Juan Ignacio Marín; Natalia Ratusnu; Estela Manero; Daniela Perez; Marina Villa; Federico Orozco; Dolores Murga; Sebastián Marciano; Fernando Bessone; Marcelo Silva; Manuel Mendizabal;

Gender disparity in hepatocellular carcinoma recurrence after curative hepatectomy Tianyi Liang; Yongfei He; Shutian Mo; Zijun Chen; Xiwen Liao; Xin Zhou; Chengkun Yang; Shuqi Zhao; Chuangye Han; Guangzhi Zhu; Hao Su; Xinping Ye; Tao Peng;